Text Size

Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2008 by Imperial College London.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00230672
First received: September 29, 2005
Last updated: August 12, 2008
Last verified: August 2008
History of Changes
  Purpose

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels, including arteriovenous malformations in the lungs (PAVMs). We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of several proteins in the blood stream. We propose to take blood samples from patients at defined times in order to study changes in blood protein levels and activity


Condition
Telangiectasia, Hereditary Hemorrhagic

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Studies of Plasma Proteins Derived From Pulmonary Arteriovenous Malformation Patients

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Imperial College London:

Estimated Enrollment: 70
Study Start Date: March 2005
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:Patients with hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations -

Exclusion Criteria:Unable to provide informed consent

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00230672

Contacts
Contact: Claire Shovlin 0208 383 1000 c.shovlin@imperial.ac.uk

Locations
United Kingdom
Imperial College Hammersmith Campus Recruiting
London, United Kingdom, W12 0NN
Contact: Claire Shovlin     0208 383 1000     c.shovlin@imperial.ac.uk    
Sponsors and Collaborators
Imperial College London
Investigators
Principal Investigator: Claire Shovlin Imperial College London
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00230672     History of Changes
Other Study ID Numbers: IC/CLS7
Study First Received: September 29, 2005
Last Updated: August 12, 2008
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Arteriovenous Malformations
Vascular Malformations
Cardiovascular Abnormalities
Congenital Abnormalities
Telangiectasia, Hereditary Hemorrhagic
Telangiectasis
 Cardiovascular Diseases
Vascular Diseases
Hemostatic Disorders
Hemorrhagic Disorders
Hematologic Diseases

ClinicalTrials.gov processed this record on May 16, 2013